Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.
Eric Smith, MD, PhD
Advertisement
Articles by Eric Smith, MD, PhD
Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.
Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses CD19 (19-28Z) CAR T-cell therapy in B-cell acute lymphoblastic leukemia.
Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Smith Discusses CAR T Cells in Multiple MyelomaPublished: March 28th 2017 | Updated:
Dr. Smith Discusses CD19 CAR T-Cell Therapy in B-ALLPublished: June 25th 2017 | Updated:
Dr. Smith Discusses Novel CAR T-Cell Therapies for MyelomaPublished: September 27th 2018 | Updated:
Dr. Smith Discusses CAR T Cell Persistence in MyelomaPublished: November 2nd 2018 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program
2
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
3
Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025
4
BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again
5
